Pharmacology
The first-pass effect (also known as first-pass metabolism or presystemic metabolism) is a phenomenon of drug metabolism whereby the concentration of a drug is greatly reduced before it reaches the systemic circulation. It is the fraction of a drug lost during the process of absorption, generally related to the liver and gut wall. This effect is a major factor in determining the bioavailability of orally administered drugs and often necessitates higher oral doses or alternative routes of administration.1
The first-pass effect occurs primarily in the liver, but also in the gut wall, and to a lesser extent in the lungs and blood. After oral administration, a drug is absorbed from the gastrointestinal tract and transported via the portal vein to the liver before reaching the systemic circulation. In the liver, enzymes such as cytochrome P450 (CYP) oxidize, reduce, or hydrolyze the drug, often converting it into more water-soluble metabolites for excretion. The gut wall also contains CYP enzymes and efflux transporters like P-glycoprotein that can limit absorption. The combined effect can be so extensive that some drugs, such as nitroglycerin, are almost completely inactivated before reaching systemic blood, making oral administration ineffective.
The first-pass effect has significant clinical consequences. For drugs with high first-pass metabolism, oral doses must be much larger than intravenous doses to achieve the same therapeutic effect. For example, propranolol has an oral bioavailability of only about 25% due to extensive hepatic metabolism. This variability can lead to unpredictable drug levels among patients, especially those with liver disease or genetic polymorphisms in CYP enzymes. To bypass first-pass metabolism, alternative routes such as sublingual, buccal, rectal, transdermal, or intravenous administration are used. Sublingual administration, for instance, allows direct absorption into the systemic circulation via the lingual veins, avoiding portal circulation. This is why nitroglycerin is given sublingually for angina.
Several factors influence the extent of first-pass metabolism. Liver blood flow, enzyme activity, and the drug's intrinsic clearance are key determinants. High hepatic blood flow can increase the amount of drug delivered to the liver, but also increases the rate of metabolism. Enzyme induction (e.g., by rifampin) or inhibition (e.g., by grapefruit juice) can alter first-pass metabolism dramatically. Genetic polymorphisms in CYP2D6, CYP2C19, and other enzymes lead to poor, intermediate, extensive, or ultrarapid metabolizer phenotypes, causing wide interindividual variability in drug exposure. Age, diet, and disease states such as cirrhosis also affect first-pass metabolism. For example, in cirrhosis, reduced hepatic function can increase oral bioavailability of drugs like morphine, leading to enhanced effects and toxicity.2
Beyond the liver, the first-pass effect can occur in the gut wall, lungs, and even the blood. The gut wall metabolism is particularly important for drugs like cyclosporine and verapamil. Some drugs undergo first-pass metabolism in the intestinal lumen by bacterial enzymes, which can be altered by antibiotics. The lungs can also metabolize drugs, though this is less studied. Prodrugs are designed to exploit first-pass metabolism: they are inactive until converted to the active form in the liver. For example, enalapril is a prodrug that is hydrolyzed to enalaprilat. The first-pass effect is also relevant in veterinary medicine and in drug development, where it is a major cause of low oral bioavailability. In some cases, the first-pass effect can be saturable, meaning that at high doses, the metabolic enzymes become saturated, leading to a disproportionate increase in bioavailability—a phenomenon seen with drugs like propranolol and verapamil.3
The first-pass effect is a key consideration in drug development and clinical dosing, often requiring careful route selection and dose adjustment.
Help improve the encyclopedia. Reports go straight to the site manager.